200
Participants
Start Date
March 31, 2006
Primary Completion Date
February 28, 2010
Study Completion Date
August 31, 2010
Rituximab
Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
Placebo
"Treatment Group A: placebo infusion at Weeks 8 and 9~Treatment Group B: placebo infusion at Weeks 0 and 1"
Hospital for Special Surgery (Adult Site), New York
North Shore Long Island Jewish Health System (Adult Site), Lake Success
Children's Hospital of Pittsburgh (Pediatric Site), Pittsburgh
University of Pittsburgh / UPMC (Adult Site), Pittsburgh
Children's Hospital of Philadelphia (Pediatric Site), Philadelphia
University of Pennsylvania (Adult Site), Philadelphia
National Institute of Health (Adult Site), Bethesda
National Institute of Health (Pediatric Site), Bethesda
Duke University Medical Center (Pediatric Site), Durham
University of Miami School of Medicine (Adult Site), Miami
Miami Children's Hospital (Pediatric Site), Miami
University of Alabama Arthritis Intervention Program (Adult Site), Birmingham
Kentucky Clinic (Adult Site), Lexington
Cincinnati's Children's Hospital (Pediatric Site), Cincinnati
University of Michigan Health System (Adult Site), Ann Arbor
Michigan State University (Adult and Pediatric Site), Grand Rapids
Medical College of Wisconsin / Froedtert Memorial Luthern Hospital (Adult Site), Milwaukee
Mayo Clinic (Adult Site), Rochester
Mayo Clinic (Pediatric Site), Rochester
University of Kansas Medical Center (Adult Site), Kansas City
Phoenix Neurological Associates, LTD (Adult Site), Phoenix
Cedars-Sinai Medical Center (Adult Site), Los Angeles
Stanford University (Adult Site), Stanford
Stanford University (Pediatric Site), Stanford
Children's Hospital of Boston (Pediatric Site), Boston
Beth Israel Deaconess Medical Center (Adult Site), Boston
University of Texas Southwestern Medical Center (Adult), Dallas
IWK Health Centre, Halifax
Hospital for Sick Children (Pediatric Site), Toronto
Institute of Rheumatology, Prague
Karolinska Institute, Stockholm
Collaborators (2)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Genentech, Inc.
INDUSTRY
Biogen
INDUSTRY
University of Pittsburgh
OTHER